Alx Oncology Holdings (ALXO) Share-based Compensation (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Share-based Compensation data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 51.9% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 159.54% YoY), and the FY2025 full-year result was $12.6 million, down 56.1% from the prior year.
• Share-based Compensation eased to $2.5 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q3 2023 to a low of -$19.6 million in Q4 2024.
• A 5-year average of $1.0 million and a median of $861000.0 in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 3332.97% in 2023 and plunged 391.67% in 2024, its largest moves.
• Tracing ALXO's Share-based Compensation over 5 years: stood at -$4.1 million in 2022, then soared by 263.25% to $6.7 million in 2023, then tumbled by 391.67% to -$19.6 million in 2024, then surged by 113.8% to $2.7 million in 2025, then slipped by 7.28% to $2.5 million in 2026.
• Business Quant data shows ALXO's Share-based Compensation at $2.5 million in Q1 2026, $2.7 million in Q4 2025, and $2.5 million in Q3 2025.